🚀 #GateNewbieVillageEpisode4 ✖️ @比特一哥 
📈 Follow the trend, pick your points, wait for the signal 
💬 Share your trading journey | Discuss strategies | Grow with the Gate Family 
⏰ Event Date: Oct 25 04:00 – Nov 2 16:00 UTC 
How to Join: 
1️⃣ Follow Gate_Square + @比特一哥 
2️⃣ Post on Gate Square with the hashtag #GateNewbieVillageEpisode4  
3️⃣ Share your trading growth, insights, or experience 
— The more genuine and insightful your post, the higher your chance to win! 
🎁 Rewards 
3 lucky participants → Gate X RedBull Cap + $20 Position Voucher 
If delivery is unavailable, replaced with a $30 Position V
One-hundred million red: The latest clinical results of the innovative drug deuterated benzbromarone (AR882) for the treatment of gout stones were published at ACR 2025.
Jin10 data reported on October 29th, Yipinhong announced that the latest clinical results of its innovative gout drug deuterated benzbromarone (AR882) for the treatment of gout stones were released at ACR2025 (American College of Rheumatology Annual Meeting). Clinical conclusions show that for patients with newly treated and refractory gout stones, monotherapy with deuterated benzbromarone or combination therapy with allopurinol can effectively drop sUA, reduce urate crystal burden, and achieve a high complete dissolution rate of targeted gout stones. Monotherapy or combination therapy with deuterated benzbromarone can provide a more effective treatment option for patients with chronic gout stones who have poor efficacy with existing treatment regimens.